Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 120 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vaginal product Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of the Vaginal Gel PRO 2000/5

NCT00006207
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 2000
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug Treatment

NCT03682601
View directory record Official record
Conditions
Sexual Pain Disorders, Postmenopausal Symptoms, Vulvovaginal Atrophy, Female Sexual Dysfunction, Dyspareunia, Vulvodynia, Vestibulodynia, Arousal Disorders, Sexual, Genito-Pelvic Pain/Penetration Disorder, Female Sexual Arousal Disorder
Interventions
5% sinecatechins ointment, Placebo, 10% sinecatechins ointment
Drug
Lead sponsor
GTO Pharmaceutical, LLC
Other
Eligibility
20 Years to 70 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
4
States / cities
New York, New York • Nyack, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United States

NCT00799058
View directory record Official record
Conditions
HIV-1 Infections
Interventions
dapivirine 4789, dapivirine gel 4759, Drug placebo
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
5
States / cities
Birmingham, Alabama • Torrance, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Phase 3 Interventional

Estrogen Administration for the Treatment of NASH in Postmenopausal Women

NCT04833140
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Estradiol patch, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single Group Study to Evaluate the Effects of a Vaginal Probiotic on Vaginal and Digestive Health

NCT06124313
View directory record Official record
Conditions
Irritable Bowel Syndrome, Vaginal Health
Interventions
Vaginal Probiotic
Dietary Supplement
Lead sponsor
Rael
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hormonal Contraception and Vaginal Health

NCT00612508
View directory record Official record
Conditions
Contraceptive Usage, Vaginal Epithelial Disruption
Interventions
Desogen (ethinyl estradiol and desogestrel), NuvaRing (ethinyl estradiol and etonogestrel)
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 8, 2012 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Exploratory Rectal Safety Study of Three Tenofovir Gel Formulations

NCT01575418
View directory record Official record
Conditions
HIV Prevention
Interventions
Rectal formulation (RF) of tenofovir 1% gel, Vaginal formulation (VF) of tenofovir 1% gel, Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel, Radiolabeling of study drugs and semen
Drug · Radiation
Lead sponsor
Ian McGowan
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Trial of Cervidil for Outpatient Pre-induction of Cervical Ripening

NCT03806231
View directory record Official record
Conditions
Induction of Labor Affected Fetus / Newborn
Interventions
Outpatient Dinoprostone 10mg, Inpatient Dinoprostone 10 mg
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
St. George, Utah
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial

NCT02447029
View directory record Official record
Conditions
Pregnancy, Unwanted
Interventions
vaginal 2% Xylocaine, standard lidocaine paracervical block
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Not applicable Interventional

Platelet Rich Plasma as an Adjunct Therapy at the Time of Transvaginal Native Tissue Prolapse Surgery

NCT05731284
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Platelet rich plasma (PRP) Injection, Placebo
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

NCT04214067
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
Interventions
Biospecimen Collection, Brachytherapy, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Radiation · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
275
States / cities
Birmingham, Alabama • Clovis, California • Concord, California + 195 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

NCT02210689
View directory record Official record
Conditions
BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe
Interventions
clindamycin phosphate vaginal cream 2%, placebo
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Mesa, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia

NCT03171480
View directory record Official record
Conditions
Preeclampsia, Labor, Premature
Interventions
Monoket Pill, Placebo
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 21, 2026, 1:15 AM EDT
Recruiting Not applicable Interventional

Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

NCT07544667
View directory record Official record
Conditions
Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
Interventions
Poly-L-Lactic Acid (Sculptra) injection, Placebo injection (sterile water)
Device · Other
Lead sponsor
Cassandra Kisby
Other
Eligibility
21 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Will Cleaning the Bowel With an Enema Before Vaginal Prolapse Surgery Prevent Complications?

NCT00981539
View directory record Official record
Conditions
Colon Cleansing
Interventions
enema
Procedure
Lead sponsor
Illinois Urogynecology, Ltd.
Other
Eligibility
18 Years and older · Female only
Enrollment
310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Oak Lawn, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2009 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

LACTIN-V Study for Recurrent Bacterial Vaginosis

NCT02766023
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Lactobacillus crispatus CTV-05, Metronidazole, Placebo
Biological · Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Trial to Assess the Pharmacokinetics and Pharmacodynamics of a Novel Synbiotic Oral Supplement for Vaginal Health

NCT07435350
View directory record Official record
Conditions
Vaginal Health
Interventions
Vaginal Health Placebo Control, Vaginal Health Active VV-01
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 60 Years · Female only
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Phase 2 Interventional

REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy

NCT01984138
View directory record Official record
Conditions
Estrogen Receptor Positive Breast Cancer, Breast Cancer
Interventions
ESTRING, Replens, Vagifem
Drug
Lead sponsor
Polly A. Niravath, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

NCT01448616
View directory record Official record
Conditions
Herpes Simplex Type II
Interventions
TDF, Placebo Vaginal Gel, Vaginal TFV Gel, Placebo Tablets
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of the Vaginal Microbicide Agent 1% Tenofovir Gel

NCT00561496
View directory record Official record
Conditions
HIV Infections
Interventions
Tenofovir gel
Drug
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 28, 2008 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy of Extended-Release Liposomal Bupivacaine for Post-Partum Pain Management Following Obstetrical Laceration

NCT03152877
View directory record Official record
Conditions
Pain, Obstetric
Interventions
Bupivacaine Liposome Injectable Product, 0.25% plain bupivacaine
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study to Treat Bacterial Vaginosis

NCT01621399
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Product 55394, Placebo Vehicle (non-treatment)
Drug
Lead sponsor
Medicis Global Service Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
651 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Mesa, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Flourish Vaginal Care System to Establish Neovaginal Microbiome

NCT05372770
View directory record Official record
Conditions
Neovaginal Microbiome
Interventions
Flourish Vaginal Care system
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
New Hope, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 21, 2026, 1:15 AM EDT